Articles published by CytoDyn Inc.
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
November 04, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
October 08, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
October 04, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 24, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
September 2024 Letter to Shareholders
September 09, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
November 2023 Letter to Shareholders
November 03, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From CytoDyn Inc.
Via Business Wire
Tickers
CYDY
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
January 13, 2022
From CytoDyn Inc.
Via Business Wire
Tickers
CYDY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.